ClinicalTrials.gg
CompletedNCT00764361Updated Apr 7, 2017Results posted

Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers

A Phase 2 interventional study of doxycycline and placebo gel in Diabetic Foot Ulcer, sponsored by NanoSHIFT LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by NanoSHIFT LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 85 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
267th of 322
15 · median 60
Started
2009
with 7 others
Phase 2
43 of 381
5 open now
Registered
34th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 267th largest by enrollment of the 322 interventional ones that give a count, is one of 8 that started in 2009, is one of 43 in phase 2, and was the 34th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Diabetic Foot studies recruiting now, 96 (70%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

This study is a double-blind, one center, two-arm study with a two (2) week Run-In, evaluating the efficacy of a once-daily administration of NanoDOX™ Hydrogel topically applied to diabetic ulcers in concert with professionally administered Standard of Care (SOC) procedures as described by Standard Operating Procedure(s) of the Department of Veterans Administration Hospitals. During the run-in period patients with infected wounds will receive oral antibiotic and not be included in the topical portion of the study until the infection is shown by wound fluid analysis to be resolved. Following a two (2) week Run-In of all patients to receive SOC treatment for diabetic ulcers, patients would have either the investigational material or the placebo hydrogel applied as a part of their wound care. Each patient would receive 1.5 gm packets of either the test article or the placebo hydrogel for a once-daily home treatment accompanied by a dressing change.

Read the detailed description

Study of NanoDOX vs placebo on diabetic ulcers of the lower leg/foot.

03

Conditions studied

  • Diabetic Foot Ulcer

Keywords

  • Diabetic
  • Ulcer
  • Wound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a documented history of type I or type II diabetes mellitus as defined by the American Diabetes Association
  • Women of must have a negative urine pregnancy test at screening and at baseline, and:

    • Agree to use a double-barrier method of during their participation in this study;
    • condoms (with spermicide) and hormonal contraceptives OR
    • condoms (with spermicide) and intrauterine device OR
    • intrauterine device and hormonal contraceptives OR
    • Abstains from sexual intercourse during their participation in this study OR
    • Is with a same-sex partner and does not participate in bisexual activities where there is a risk of becoming pregnant
  • Have an ulcer on the lower extremity (distal to a line connecting the medial and lateral malleoli) that has been present for at least 3 weeks and that is 1.2 cm2 to 4.0 cm2 at initial screening
  • Be able to apply study drug to their ulcer, or have a caregiver do it
  • Adequate blood flow to target ulcer extremity as measured by transcutaneous oxygen tension (TcpO2) of >30mmHg
  • Target ulcer is Grade I according to the Wagner Grading Scale
  • Quantitative bacterial count of of \< 1.0 x 1.0E5 per gram of tissue for non-infected ulcers
  • Quantitative bacterial count of ≥ 1.0 x 1.0E5 per gram of tissue for infected ulcers

Exclusion criteria

Exclusion Criteria:

  • Be a pregnant or lactating woman or a female of who is not practicing acceptable form of .
  • Allergy to tetracycline, minocycline, demeclocycline, or any other known tetracycline derivative
  • Have more than three chronic ulcers present at baseline
  • Have undergone treatment with system or therapy in the past 2 months
  • Have connective tissue disease
  • Currently be going through kidney dialysis for renal failure
  • Have undergone treatment with doxycycline, Procuren®, or Regranex® within the last 30 days
  • Have participated in another clinical research trial within the last 30 days
  • Have a known history of osteomyelitis affecting to the area where the target ulcer is present
  • Have any other concomitant condition which, in the opinion of the investigator, would make the subject unsuitable for the study.
  • Subject has ulcers resulting from any cause other than diabetes (electrical burn, arterial insufficiency, chemical or radiation insult)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    NanoDOX™ Hydrogel

    1.0% doxycycline gel

    Drug: doxycycline

  • Placebo comparator
    Placebo

    placebo gel

    Drug: placebo gel

Interventions

  • 1.0% doxycycline gel applied topically to the wound once daily for 20 weeks

  • Drugplacebo gel

    placebo gel applied topically to the wound once daily for 20 weeks

    Also known as: doxycycline

06

What researchers measure

Primary outcomes

  1. Number of Participants Without Adverse Events

    Participants were monitored for 20 weeks during the study.

    Time frame: every 2 weeks

Secondary outcomes

  1. Analyze the Molecular Changes in Pro-inflammatory Cytokine Levels That Occur in Diabetic Foot Ulcers as a Function of Healing Rate in the Presence /Absence of NanoDOX Hydrogel (1% Doxycycline Monohydrate Gel)

    Time frame: baseline, week 4, week 10, week 20

07

Results

Posted Apr 5, 2012
Limitations and caveats
enrollment stopped before reaching the initial 40 subjects anticipated due to slow enrollment of subjects

Participant flow

subjects were recruited through the local veterans administration clinics

Participant flow — Overall Study
MilestoneNanoDOX™ HydrogelPlacebo
Started87
Completed63
Not completed24
Withdrew: Withdrawal by subject23
Withdrew: Adverse event01

Outcome measures

PrimaryNumber of Participants Without Adverse Events

Participants were monitored for 20 weeks during the study.

Time frame:
every 2 weeks
Reported as:
Number · participants
Number of Participants Without Adverse Events
participantsNanoDOX™ HydrogelPlacebo
Number of Participants Without Adverse Events87
SecondaryAnalyze the Molecular Changes in Pro-inflammatory Cytokine Levels That Occur in Diabetic Foot Ulcers as a Function of Healing Rate in the Presence /Absence of NanoDOX Hydrogel (1% Doxycycline Monohydrate Gel)
Time frame:
baseline, week 4, week 10, week 20

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NanoDOX™ Hydrogel—0/8 (0%)0/8 (0%)
Placebo—0/7 (0%)0/7 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)NanoDOX™ HydrogelPlaceboTotal
<=18 years000
Between 18 and 65 years538
>=65 years347
Age, Continuous
Age, Continuous(years)NanoDOX™ HydrogelPlaceboTotal
Mean64.99 ± 11.5368.86 ± 9.7566.33 ± 10.53
Sex: Female, Male
Sex: Female, Male(Participants)NanoDOX™ HydrogelPlaceboTotal
Female000
Male8715
Region of Enrollment
Region of Enrollment(participants)NanoDOX™ HydrogelPlaceboTotal
United States8715
08

Study locations

1 site
  • North Florida / South Georgia Veterans Administration Hospital
    Gainesville, Florida 32608, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2008
First posted
Oct 2, 2008
Start
Jan 2009
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Results first posted
Apr 5, 2012
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00764361
Lead sponsor
NanoSHIFT LLC
Responsible party
Sponsor
First posted
Oct 2, 2008
Start date
Jan 2009
Primary completion
Aug 2010
Completion
Aug 2010
Results posted
Apr 5, 2012
Last update
Apr 7, 2017

Study contacts

John Abernethy, MD
study director · Resilience Government Services, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion